These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38743316)

  • 1. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
    King TL; Voon PJ; Yuen KH; Mohamed Noor DA
    Support Care Cancer; 2024 May; 32(6):345. PubMed ID: 38743316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
    Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
    JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
    Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
    Santhosh A; Sharma A; Bakhshi S; Kumar A; Sharma V; Malik PS; Pramanik R; Gogia A; Prasad CP; Sehgal T; Gund S; Dev A; Cheung WY; Pandey RM; Kumar S; Gupta I; Batra A;
    J Clin Oncol; 2024 May; 42(15):1821-1829. PubMed ID: 38412399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
    Scontre VA; Martins JC; de Melo Sette CV; Mutti H; Cubero D; Fonseca F; Del Giglio A
    J Diet Suppl; 2018 Sep; 15(5):606-612. PubMed ID: 29095653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
    Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
    Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
    Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
    Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Single-Blinded Phase II Trial Comparing Efficacy and Quality of Life of Topical Aloe Vera Gel Plus Urea Cream Versus Urea Cream Alone for Prevention of Hand Foot Syndrome in Cancer Patients Receiving Capecitabine.
    Wanichtanom L; Vrakornvoravuti G; Boonsiri M; Suthepwanon A
    Asian Pac J Cancer Prev; 2024 Jun; 25(6):2203-2210. PubMed ID: 38918684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
    Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
    Trials; 2022 May; 23(1):420. PubMed ID: 35590388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
    Schmulenson E; Krolop L; Simons S; Ringsdorf S; Ko YD; Jaehde U
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):435-444. PubMed ID: 32852627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors of Capecitabine-Induced Hand-Foot Syndrome: A Single-Institution, Retrospective Study.
    Kanbayashi Y; Taguchi T; Ishikawa T; Otsuji E; Takayama K
    Oncology; 2023; 101(7):407-414. PubMed ID: 37075722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
    Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
    Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
    de With M; van Doorn L; Maasland DC; Mulder TAM; Oomen-de Hoop E; Mostert B; Homs MYV; El Bouazzaoui S; Mathijssen RHJ; van Schaik RHN; Bins S
    Biomed Pharmacother; 2023 Mar; 159():114232. PubMed ID: 36630849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
    Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
    Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
    Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
    Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
    Kruger S; Boeck S; Heinemann V; Laubender RP; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler TC; Fischer von Weikersthal L; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Modest DP; Stintzing S; Haas M
    Acta Oncol; 2015 Jul; 54(7):993-1000. PubMed ID: 25924969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
    Ostwal V; Kapoor A; Mandavkar S; Chavan N; Gupta T; Mirani J; Saklani A; Desouza A; Murugan K; Nashikkar C; Gupta S; Ramaswamy A
    Oncologist; 2020 Dec; 25(12):e1886-e1892. PubMed ID: 32717127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
    Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
    Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.